Uterine leiomyosarcoma: A review of the literature and update on management options

Keyphrases

• Management Options 100%
• Adjuvant Therapy 66%
• Early Disease 66%
• Clinical Trials 33%
• Tumor 33%
• Management Strategy 33%
• Clinical Presentation 33%
• Overall Survival 33%
• Surgical Resection 33%
• Epidemiology 33%
• Mitotic Index 33%
• Malignancy-associated 33%
• Clinical Benefit 33%
• Hysterectomy 33%
• Histologic 33%
• Multidrug-resistant 33%
• Most Common Form 33%
• Recurrent Disease 33%
• Pathologic Characteristics 33%
• Advanced Disease 33%
• Oophorectomy 33%
• Uterine Sarcoma 33%
• Targeted Therapy 33%
• Lymph Node Dissection 33%
• Leiomyosarcoma 33%
• Presenting Symptoms 33%
• Tumor Necrosis 33%
• Complete Surgical Resection 33%
• Perimenopausal 33%
• Cytological Atypia 33%
• Pembrolizumab 33%
• Nivolumab 33%
• Mesenchymal Tumor 33%
• Preoperative Diagnosis 33%
• Pazopanib 33%

Medicine and Dentistry

• Leiomyosarcoma 100%
• Neoplasm 50%
• Adjuvant Therapy 50%
• Surgery 50%
• Diseases 50%
• Clinical Trial 25%
• Overall Survival 25%
• Cohort Effect 25%
• Recurrent Disease 25%
• Mitotic Index 25%
• Cancer 25%
• Hysterectomy 25%
• Retroperitoneal Lymph Node Dissection 25%
• Ovariectomy 25%
• Targeted Therapy 25%
• Tumor Necrosis 25%
• Immunotherapy 25%
• Chemotherapy 25%
• Pazopanib 25%
• Nivolumab 25%
• Pembrolizumab 25%